Abbott Xinlay Review By Oncologic Committee Expected In Mid-September
Executive Summary
Review of Abbott's Xinlay by FDA's Oncologic Drugs Advisory Committee for treatment of metastatic hormone-refractory prostate cancer will likely take place in mid-September
You may also be interested in...
Abbott Looks To Xinlay Back-Up Study After Negative Advisory Cmte. Review
Abbott is counting on its back-up Phase III study to support Xinlay approval should FDA follow the recommendation of its Oncologic Drugs Advisory Committee and reject the current application
Abbott Looks To Xinlay Back-Up Study After Negative Advisory Cmte. Review
Abbott is counting on its back-up Phase III study to support Xinlay approval should FDA follow the recommendation of its Oncologic Drugs Advisory Committee and reject the current application
Abbott Sees Atrasentan Market Opportunity In Less Advanced Prostate Cancer
Abbott sees a market opportunity for atrasentan in prostate cancer patients with less advanced disease based on the company's initial subset analysis of an unfavorable Phase III study for the endothelin-1 receptor antagonist